Literature DB >> 22943900

[Correlation between interleukin-28B genetic polymorphisms and primary hepatocellular carcinoma].

Yan Wang1, Heng-hui Zhang, Yan-hui Chen, Xing-wang Xie, Wei-jia Liao, Li-ling Qin, Xiu-yun Sun, Ran Fei, Xue-yan Wang, Lai Wei, Hong-song Chen, Ming-hui Mei.   

Abstract

OBJECTIVE: To explore the correlation between single nucleotide polymorphisms (SNPs) of interleukin-28B (IL-28B) gene and the susceptibility to primary hepatocellular carcinoma (HCC).
METHODS: A total of 300 histologically confirmed HCC cases (from November 2001 to April 2010) and 310 healthy controls with no history of chronic hepatitis B or hepatocellular carcinoma (2009-2010) were selected from a hospital in Guilin and a hospital in Beijing for this case-control study.139 HCC patients in the case group had complete clinical tracking data. All the subjects were Han Chinese, with no age or gender restrictions.2 ml peripheral blood samples were drawn from each subject with informed consent. SNP of rs12972991, rs4803223, rs8099917 and rs12979860 four loci in IL-28B gene were analyzed by matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF).
RESULTS: The frequencies of C allele at rs12972991, G allele at rs8099917 and G allele at rs4803223 were 6.7% (40/598), 7.9% (47/598) and 10.0% (59/588) respectively in case group; all higher than the corresponding frequencies in control group, separately 2.9% (18/618), 4.1% (25/616) and 3.6% (21/608). The differences were statistically significant (χ2=9.542, 7.858, 20.736, P values all<0.05). The above alleles could increase the risk of HCC, and the OR (95%CI) values were separately 1.67 (1.13-2.46), 1.49 (1.08-2.06) and 2.91 (1.79-4.72). The genotype frequencies of AC+CC at rs12972991, GT+GG at rs8099917, GA+GG at rs4803223 were 13.0% (39/299), 14.7% (44/299) and 19.0% (56/296) respectively in case group; while the frequencies were lower in control group, separately 5.8% (18/309), 8.1% (25/308) and 6.6% (20/304). The differences were statistically significant (χ2=9.319, 6.557, 20.948, P values all<0.05). These genotypes may increase the risk of HCC, and the adjusted OR (95%CI) values were 2.24 (1.31-3.83), 1.81 (1.14-2.88) and 2.90 (1.78-4.70), respectively. The stratified analysis of the clinical data indicated that the frequency of genotype GA+GG at rs4803223 was 50.0% (13/26) in patients of tumor thrombosis in portal vein (TTPV), higher than the frequency of genotype AA (21.1%, 23/109). The difference was statistically significant (χ2=8.965, P=0.003).
CONCLUSION: The results suggested that IL-28B gene polymorphisms was correlated to the susceptibility to HCC in Chinese Han ethnic population. Among them, GA + GG genotype at rs4803223 could increase the risk of TTPV in HCC patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22943900

Source DB:  PubMed          Journal:  Zhonghua Yu Fang Yi Xue Za Zhi        ISSN: 0253-9624


  4 in total

1.  Influence of interleukin-28B polymorphism on progression to hepatitis virus-induced hepatocellular carcinoma.

Authors:  Jinxia He; Guoqing Yu; Zhizhong Li; Houjie Liang
Journal:  Tumour Biol       Date:  2014-05-30

2.  Association of polymorphisms in interleukin-18 and interleukin-28B genes with outcomes of hepatitis B virus infections: a meta-analysis.

Authors:  Pu Xia; Mo Zhou; Dao Song Dong; Ya-Nan Xing; Yang Bai
Journal:  Tumour Biol       Date:  2013-09-12

3.  The influence of interleukin 28B polymorphisms on the risk of hepatocellular carcinoma among patients with HBV or HCV infection: An updated meta-analysis.

Authors:  Shaoyou Qin; Jiangbin Wang; Changyu Zhou; Yan Xu; Yonggui Zhang; Xu Wang; Song Wang
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

Review 4.  Meta-analysis of associations of interleukin-28B polymorphisms rs8099917 and rs12979860 with development of hepatitis virus-related hepatocellular carcinoma.

Authors:  Yu Zhang; Shao-Liang Zhu; Jie Chen; Le-Qun Li
Journal:  Onco Targets Ther       Date:  2016-05-30       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.